Navigation Links
K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P
Date:10/13/2011

Inquiries" of the Notes to the Consolidated Financial Statements in Part I of this Report could result in significant civil fines or penalties, including exclusion from participation in federal healthcare programs such as Medicare and Medicaid;
  • delays in returning, or failure to return, certain or many of the Company's approved products to market, including loss of market share as a result of the suspension of shipments, and related costs;
  • the ability to sell or license certain assets, and the purchase prices, milestones, terms and conditions of such transactions;
  • the possibility that default on one type or class of the Company's indebtedness could result in cross-default under, and the acceleration of, its other indebtedness;
  • the risks that present or future changes in the Board of Directors or management may lead to an acceleration of the Company's debt or to adverse actions by government agencies or our auditors;
  • the risk that even though the price and 30-day average price of the Company's Class A Common Stock and Class B Common Stock currently satisfy the quantitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float, the Company can provide no assurance that they will remain at such levels thereafter;
  • compliance with debt covenants; and
  • the risks detailed from time-to-time in the Company's filings with the SEC.

    • This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements. Because the factors referred to above, as well as the statements included under the captions Part I, Item 1A—"Risk Factors," Part II, Item 7—"Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the Company's 2011 Form 10-K, could cause actual results or outcomes to differ materially from those expressed in any fo
    '/>"/>

    SOURCE K-V Pharmaceutical Company
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
    9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/18/2013)... June 18, 2013 The board of directors ... ) has declared a dividend for the third quarter ... stock. The dividend is payable September ... of business on August 15, 2013. Lilly, ... of pharmaceutical products by applying the latest research from ...
    (Date:6/18/2013)... Today, Wall Street Reports announced new research reports ... Management Associates Inc. (NYSE: HMA ), IDEXX Laboratories, ... ISIS ), and Trius Therapeutics Inc. (NASDAQ: TSRX). ... including full price targets, industry analysis and analyst ratings - ... Report On June 7, 2013, Gilead Sciences Inc. ...
    (Date:6/18/2013)... And EMERYVILLE, Calif. , ... presented final results today from a Phase 2/3 ... capsules demonstrating a statistically significant improvement in levodopa-induced ... at week 8 versus placebo in the Unified ... extended-release formulation of amantadine intended for once-nightly administration ...
    Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6
    ... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
    ... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
    Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
    (Date:6/18/2013)... 2013 Healthcare Solutions , ... Procura Management, today announced the appointment of Richard ... In this position, Leonardo will direct Healthcare Solutions’ ... strategic growth initiatives. , Recognized in the property ... Leonardo brings more than 20 years of experience ...
    (Date:6/18/2013)... June 18, 2013 David Connett, DO, ... Family Medicine for the College of Osteopathic Medicine of ... has been elected president of the Osteopathic Medical ... Brown Jr. appointed Connett, a 1984 alumnus of COMP, ... recently elected Connett to the position during a conference ...
    (Date:6/18/2013)... cells in the mammary gland appear to provide a ... in life, and the subsequent development of breast cancer, ... July 2013 issue of the journal Cancer Prevention ... be associated with an increased risk of certain types ... biology of social stress to cancer have been hard ...
    (Date:6/18/2013)... a way to make phytosterol molecules from plants dispersible ... potentially opening the way to dramatic reductions in human ... new process and composition was issued on June 11. ... in animals are highly similar and when both are ... they mix in the gut of an animal, the ...
    (Date:6/18/2013)... computer guided fitness training system using a person,s ... winners of the LeWeb,13 London Startup Competition, Europe,s ... startup company, Genetrainer, building on University of Bristol ... Pethica and Julian Gough, Professor of Bioinformatics in ... from over 350 startups to be one of ...
    Breaking Medicine News(10 mins):Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4Health News:Brandeis scientist invents anti-cholesterol process 2
    ... , FRIDAY, Dec. 2 (HealthDay News) -- ... more than doubled in the United States between 1997 ... large increase of prescriptions written at outpatient clinics is ... Dorn, an assistant professor of medicine at the University ...
    ... University of Nevada, Reno and licensed through the University,s ... publication "Better World Report" for a remarkable second year ... advancement that has been licensed through IMMY, a diagnostics ... save the lives of hundreds of thousands of AIDS ...
    ... , FRIDAY, Dec. 2 (HealthDay News) -- Major depression and ... pregnant women and new mothers, a new study indicates. ... women are and what led up to these tragic events," ... medicine at the University of Michigan Medical School, said in ...
    ... The American Journal of Industrial Medicine recently published a ... at more than twice the rate of the general U.S. population ... the collapse of the WTC towers in 2001. Preliminary study results ... , Past studies have documented high rates of asthma symptoms among ...
    ... commercial stage private oncology company, has announced that prominent ... be the first to provide access to its Tumor ... of recurrent glioblastoma multiforme (GBM). GBM is a ... , The NovoTTF device, approved by the ...
    ... , FRIDAY, Dec. 2 (HealthDay News) -- ,Topical treatment ... be the first line of therapy for treating psoriasis ... from the National Psoriasis Foundation Medical Board based in ... because they cause no known adverse effects. Psoriasis, ...
    Cached Medicine News:Health News:Depression, Partner Conflict Raise Suicide Risk for Pregnant Women, New Moms 2Health News:Asthma rates double for WTC first responders 2Health News:Asthma rates double for WTC first responders 3Health News:Novocure establishes initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields Therapy 2Health News:Novocure establishes initial Clinical Centers of Excellence for Treatment of Recurrent Glioblastoma Multiforme with Tumor Treating Fields Therapy 3Health News:New Guidelines for Treating Psoriasis When Pregnant or Nursing 2
    Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
    ... take their eyes for granted. Like ... eyes need proper nutrition and care ... vision as you age. In fact, ... to maintaining and preserving eye health ...
    ... The herbal extracts, vitamins, minerals, ... increases circulation to ocular tissue, ... healthy function of the lens ... This formula is optimized to ...
    Online Unity Interlaboratory QC Data Management...
    Medicine Products: